Anoop Nambiar, MD
Basic profileThe University of Texas at San Antonio Health Science Center
Anoop Nambiar is a Respiratory physician affiliated with The University of Texas at San Antonio Health Science Center. OpenAlex indexes 80 publications with 4,972 citations (h-index 25).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
527 N Leona St
San Antonio, TX 782073110
Telephone
210-358-3038Registry record last updated 17 Mar 2011.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202518 payments$18,805openpaymentsdata.cms.gov ↗
- United Therapeutics CorporationProgram year20255 payments
- Amgen Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
61.5%beta2-Adrenergic Agonist37.8%Albuterol53%Albuterol Sulfate Hfa39%Ventolin Hfa7%Part D + Part B≥78 patientsCorticosteroid22%Trelegy Ellipta36%Symbicort24%Breztri Aerosphere17%Breyna13%Breo Ellipta10%Part D<11 patients+ 1 more class in this area
Anti-infectives
16.4%Short-acting sulfonamides13.8%Sulfamethoxazole-Trimethoprim100%Part D≥45 patientsSulfone0.9%Dapsone100%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
11.9%Kinase inhibitor8.7%Ofev100%Part D≥17 patientsPyridone3.2%Pirfenidone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis
Therapeutic Advances in Respiratory Disease
2025 - Diagnostic and prognostic trajectories of interstitial lung diseases after the multidisciplinary discussion
Therapeutic Advances in Respiratory Disease
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Marcos Restrepo, MD, MSc
The University of Texas at San Antonio Health Science Center
Robert Brzyski, MD
The University of Texas at San Antonio Health Science Center
Devjit Tripathy, MD
The University of Texas at San Antonio Health Science Center
Robert Svatek, MD
The University of Texas at San Antonio Health Science Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”